BNOX
Income statement / Annual
Last year (2025), Bionomics Limite's total revenue was $1.17 B,
and the percentage change from the previous year is not available.
In 2025, Bionomics Limite's net income was -$13.45 B.
See Bionomics Limite,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
06/30/2026 |
06/30/2025 |
06/30/2024 |
06/30/2023 |
06/30/2022 |
06/30/2021 |
06/30/2020 |
06/30/2019 |
06/30/2018 |
06/30/2017 |
| Operating Revenue |
$1.17 B |
$0.00 |
$0.00 |
$22.05 K |
$263.61 K |
$927.54 K |
$2.98 M |
$2.68 M |
$11.94 M |
$20.79 M |
| Cost of Revenue |
$0.00
|
$0.00
|
$650.41 K
|
$671.42 K
|
$16.06 M
|
$5.76 M
|
$5.80 M
|
$12.18 M
|
$25.38 M
|
$18.62 M
|
| Gross Profit |
$0.00
|
-$434.45 K
|
-$650.41 K
|
-$19.01 M
|
-$9.98 M
|
-$4.83 M
|
-$2.82 M
|
-$4.78 M
|
-$13.43 M
|
$2.17 M
|
| Gross Profit Ratio |
0
|
0
|
0
|
-862.27
|
-37.86
|
-5.21
|
-0.95
|
-1.79
|
-1.12
|
0.1
|
| Research and Development Expenses |
$3.55 B
|
$9.01 B
|
$9.42 B
|
$13.07 M
|
$11.01 M
|
$5.76 M
|
$4.00 M
|
$12.41 M
|
$26.57 M
|
$18.62 M
|
| General & Administrative Expenses |
$7.44 B
|
$7.77 B
|
$8.47 B
|
$8.91 M
|
$5.27 M
|
$5.65 M
|
$3.33 M
|
$6.55 M
|
$4.97 M
|
$5.72 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$7.44 B
|
$7.77 B
|
$8.47 B
|
$8.91 M
|
$5.27 M
|
$5.65 M
|
$3.33 M
|
$6.94 M
|
$4.97 M
|
$5.72 M
|
| Other Expenses |
$6.64 B
|
$0.00
|
$0.00
|
-$423.27 K
|
-$4.24 M
|
-$149.63 K
|
-$5.92 M
|
$0.00
|
-$20.08 M
|
-$16.02 M
|
| Operating Expenses |
$17.63 B
|
$16.78 B
|
$17.89 B
|
$21.56 M
|
$12.03 M
|
$11.26 M
|
$1.42 M
|
$19.34 M
|
$11.46 M
|
$8.32 M
|
| Cost And Expenses |
$0.00
|
$11.72 M
|
$17.89 B
|
$22.26 M
|
$263.61 K
|
$12.95 M
|
$11.72 M
|
$13.44 M
|
$36.83 M
|
$32.63 M
|
| Interest Income |
$0.00
|
$144.23 K
|
$215.92 K
|
$327.17 K
|
$10.40 K
|
$10.00 K
|
$56.46 K
|
$197.95 K
|
$422.32 K
|
$925.02 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$29.59 K
|
$46.55 K
|
$1.17 M
|
$1.79 M
|
$1.66 M
|
$1.51 M
|
$1.51 M
|
| Depreciation & Amortization |
$662.96 K
|
$662.89 M
|
$652.92 K
|
$663.19 K
|
$1.05 M
|
$1.28 M
|
$1.68 M
|
$1.68 M
|
$1.82 M
|
$1.93 M
|
| EBITDA |
$662.96 K |
-$175.11 M |
-$9.62 M |
-$20.90 M |
-$16.61 M |
-$4.97 M |
-$1.23 M |
-$11.02 M |
-$22.35 M |
-$3.58 M |
| EBITDA Ratio |
0
|
0
|
0
|
-947.83
|
-63
|
-5.35
|
-0.41
|
-4.12
|
-1.87
|
-0.17
|
| Operating Income Ratio |
-14.01
|
0
|
0
|
-977.92
|
-108.5
|
-11.07
|
-2.5
|
-4.74
|
-1.78
|
-0.27
|
| Total Other Income/Expenses Net |
$2.86 B
|
$291.09 M
|
$17.79 B
|
$39.38 K
|
-$21.95 M
|
$1.39 M
|
$1.45 M
|
$2.08 M
|
$2.00 M
|
-$733.87 K
|
| Income Before Tax |
-$13.59 B
|
-$838.00 M
|
-$97.47 M
|
-$21.52 M
|
-$21.95 M
|
-$8.88 M
|
-$6.00 M
|
-$10.62 M
|
-$19.28 M
|
-$6.25 M
|
| Income Before Tax Ratio |
-11.58
|
0
|
0
|
-976.14
|
-83.26
|
-9.57
|
-2.01
|
-3.97
|
-1.61
|
-0.3
|
| Income Tax Expense |
-$139.17 M
|
-$468.37 M
|
-$87.32 M
|
-$139.17 K
|
-$6.31 M
|
-$190.00 K
|
-$3.05 M
|
-$165.80 K
|
-$852.96 K
|
$401.64 K
|
| Net Income |
-$13.45 B
|
-$369.63 M
|
-$15.49 B
|
-$21.21 M
|
-$14.97 M
|
-$8.70 M
|
-$4.89 M
|
-$6.77 M
|
-$26.40 M
|
-$5.19 M
|
| Net Income Ratio |
-11.46
|
0
|
0
|
-962.1
|
-56.78
|
-9.38
|
-1.64
|
-2.53
|
-2.21
|
-0.25
|
| EPS |
-550.8 |
-41.4 |
-273.6 |
-477 |
-523.8 |
-361.8 |
-356.4 |
-648 |
-1693.8 |
-455.4 |
| EPS Diluted |
-550.8 |
-41.4 |
-273.6 |
-477 |
-549 |
-361.8 |
-356.4 |
-651.6 |
-1693.8 |
-455.4 |
| Weighted Average Shares Out |
$24.42 K
|
$90.16 K
|
$45.33 K
|
$45.33 K
|
$33.58 K
|
$24.07 K
|
$16.82 K
|
$16.05 K
|
$14.89 K
|
$14.86 K
|
| Weighted Average Shares Out Diluted |
$24.42 K
|
$90.16 K
|
$45.33 K
|
$45.33 K
|
$41.77 K
|
$24.07 K
|
$16.82 K
|
$16.09 K
|
$14.89 K
|
$14.86 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
